| Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE … LQM Chow, R Haddad, S Gupta, A Mahipal, R Mehra, M Tahara, R Berger, ... Journal of Clinical Oncology 34 (32), 3838-3845, 2016 | 860 | 2016 |
| Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study MS Lee, BY Ryoo, CH Hsu, K Numata, S Stein, W Verret, SP Hack, ... The Lancet Oncology 21 (6), 808-820, 2020 | 445 | 2020 |
| A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer RD Kim, V Chung, OB Alese, BF El-Rayes, D Li, TE Al-Toubah, MJ Schell, ... JAMA oncology 6 (6), 888-894, 2020 | 376 | 2020 |
| Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline/locally advanced pancreatic cancer MJ Truty, ML Kendrick, DM Nagorney, RL Smoot, SP Cleary, RP Graham, ... Annals of surgery 273 (2), 341-349, 2021 | 356 | 2021 |
| Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma L Goyal, F Meric-Bernstam, A Hollebecque, JW Valle, C Morizane, ... New England Journal of Medicine 388 (3), 228-239, 2023 | 230 | 2023 |
| First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors AR Abdul Razak, M Mau-Soerensen, NY Gabrail, JF Gerecitano, ... Journal of Clinical Oncology 34 (34), 4142-4150, 2016 | 226 | 2016 |
| Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma JP Delord, C Robert, M Nyakas, GA McArthur, R Kudchakar, A Mahipal, ... Clinical Cancer Research 23 (18), 5339-5348, 2017 | 180 | 2017 |
| Participation of the elderly population in clinical trials: barriers and solutions AC Denson, A Mahipal Cancer Control 21 (3), 209-214, 2014 | 166 | 2014 |
| Systemic therapy and sequencing options in advanced hepatocellular carcinoma: a systematic review and network meta-analysis MB Sonbol, IB Riaz, SAA Naqvi, DR Almquist, S Mina, J Almasri, S Shah, ... JAMA oncology 6 (12), e204930-e204930, 2020 | 164 | 2020 |
| Importins and exportins as therapeutic targets in cancer A Mahipal, M Malafa Pharmacology & therapeutics 164, 135-143, 2016 | 143 | 2016 |
| Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor KP Papadopoulos, R Isaacs, S Bilic, K Kentsch, HA Huet, M Hofmann, ... Cancer chemotherapy and pharmacology 75, 887-895, 2015 | 141 | 2015 |
| Phase I trial of the human double minute 2 inhibitor MK-8242 in patients with advanced solid tumors AJ Wagner, U Banerji, A Mahipal, N Somaiah, H Hirsch, C Fancourt, ... Journal of clinical oncology 35 (12), 1304-1311, 2017 | 99 | 2017 |
| A pilot study of sunitinib malate in patients with metastatic uveal melanoma A Mahipal, L Tijani, K Chan, MA Laudadio, MJ Mastrangelo, T Sato Melanoma research 22 (6), 440-446, 2012 | 96 | 2012 |
| FGFR inhibitors in oncology: insight on the management of toxicities in clinical practice A Kommalapati, SH Tella, M Borad, M Javle, A Mahipal Cancers 13 (12), 2968, 2021 | 95 | 2021 |
| Second-line therapies in advanced biliary tract cancers SH Tella, A Kommalapati, MJ Borad, A Mahipal The Lancet Oncology 21 (1), e29-e41, 2020 | 92 | 2020 |
| Early stage colon cancer: Current treatment standards, evolving paradigms, and future directions S Chakrabarti, CY Peterson, D Sriram, A Mahipal World journal of gastrointestinal oncology 12 (8), 808, 2020 | 89 | 2020 |
| Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results CD Palmer, AR Rappaport, MJ Davis, MG Hart, CD Scallan, SJ Hong, ... Nature medicine 28 (8), 1619-1629, 2022 | 87 | 2022 |
| Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: a propensity score matched analysis S Yadav, H Xie, I Bin-Riaz, P Sharma, U Durani, G Goyal, B Borah, ... European Journal of Surgical Oncology 45 (8), 1432-1438, 2019 | 87 | 2019 |
| Epidermal growth factor receptor inhibitors: coming of age A Mahipal, N Kothari, S Gupta Cancer Control 21 (1), 74-79, 2014 | 85 | 2014 |
| Contemporary management of localized resectable pancreatic cancer A Kommalapati, SH Tella, G Goyal, WW Ma, A Mahipal Cancers 10 (1), 24, 2018 | 83 | 2018 |
Albiruni Ryan Abdul RazakPrincess Margaret Cancer Centre/Mount Sinai Hospital/University of Toronto在 uhn.ca 的电子邮件经过验证
